Kiora Pharmaceuticals (7EY) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kio-104 | Macular Edema | Phase II | Recruiting | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Feb 04, 2025 | ― |
| 100 Μg Kio-301, 50 Μg Kio-301 | Retinitis Pigmentosa | Phase II | Recruiting | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | Oct 03, 2024 | ― |
| Kio-301 | Retinitis Pigmentosa, Choroideremia | phase1AndPhase2 | Recruiting | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | Mar 08, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kio-104 | Phase II | Macular Edema | Recruiting | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Feb 04, 2025 | ― |
| 100 Μg Kio-301, 50 Μg Kio-301 | Phase II | Retinitis Pigmentosa | Recruiting | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | Oct 03, 2024 | ― |
| Kio-301 | phase1AndPhase2 | Retinitis Pigmentosa, Choroideremia | Recruiting | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | Mar 08, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Kiora Pharmaceuticals, Inc. (DE:7EY) have in its pipeline
Kiora Pharmaceuticals DE:7EY is currently developing the following drugs: Kio-104, 100 Μg Kio-301, 50 Μg Kio-301, Kio-301. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
